Merck publishes innovation brochure with interactive features
- Details
- Category: Merck Group
Merck KGaA announced today that it has published a new brochure depicting how the company successfully transforms new ideas into innovative products, services and processes. The brochure concisely presents Merck innovations in pharmaceuticals, chemicals and life sciences that help to improve quality of life.
Sanofi successfully prices USD 1 billion bond issue
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of USD 1 billion of notes denominated in US dollars, due 2014, bearing interest at an annual rate of 1.20%.
New Novartis data show potential of respiratory portfolio
- Details
- Category: Novartis
Novartis has presented new Phase III data at the European Respiratory Society (ERS) congress demonstrating the potential for its portfolio of once-daily inhaled therapies to help patients with chronic obstructive pulmonary disease (COPD) to maintain more active and productive lives.
Roche's investigational medicine T-DM1 shows improvement in progression-free survival
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). The study compared trastuzumab emtansine (also known as T-DM1) to standard treatment with Herceptin (trastuzumab) plus docetaxel chemotherapy.
New Data from Phase III IMPRES Clinical Trial
- Details
- Category: Novartis
Novartis announced new data from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo[1].
Boehringer Ingelheim enrols first patient in TOviTO Phase III clinical trial program
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).
Bristol-Myers Squibb and Ambrx Announce Collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 (FGF-21) protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
More Pharma News ...
- Sanofi Pasteur Donates Vaccine Strain Used for Polio Eradication to WHO
- Bristol-Myers Squibb and Ono Enter into Strategic Agreement
- Novartis associates participate in first company-wide health and well-being initiative
- Prolia® (Denosumab) Phase 2 Extension Study
- Merck Statement on GARDASIL®
- Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
- Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe